JP2015510926A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015510926A5 JP2015510926A5 JP2015501032A JP2015501032A JP2015510926A5 JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5 JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015501032 A JP2015501032 A JP 2015501032A JP 2015510926 A5 JP2015510926 A5 JP 2015510926A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- bcp
- schizophrenia
- treat
- patient suffering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612411P | 2012-03-19 | 2012-03-19 | |
| US61/612,411 | 2012-03-19 | ||
| PCT/IB2013/052182 WO2013140342A1 (en) | 2012-03-19 | 2013-03-19 | Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015510926A JP2015510926A (ja) | 2015-04-13 |
| JP2015510926A5 true JP2015510926A5 (enExample) | 2016-05-12 |
| JP6326563B2 JP6326563B2 (ja) | 2018-05-23 |
Family
ID=49221922
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015501032A Expired - Fee Related JP6326563B2 (ja) | 2012-03-19 | 2013-03-19 | β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US20150051299A1 (enExample) |
| EP (1) | EP2827846B1 (enExample) |
| JP (1) | JP6326563B2 (enExample) |
| WO (1) | WO2013140342A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6326563B2 (ja) | 2012-03-19 | 2018-05-23 | アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド | β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 |
| BR112017018944A2 (en) | 2015-03-02 | 2018-05-15 | Afgin Pharma, Llc | method of treating a disease state or condition in humans with a carbinoid drug, and method of treating a disease state or condition in a mammal other than a human with carbinoid drug (s) |
| US10383816B2 (en) | 2015-03-02 | 2019-08-20 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with cannabinoid combination products |
| JP6397792B2 (ja) * | 2015-04-10 | 2018-09-26 | ポッカサッポロフード＆ビバレッジ株式会社 | 飲料 |
| WO2017149387A1 (en) * | 2016-03-04 | 2017-09-08 | Sharon Anavi-Goffer | Compositions of cb2 receptor selective agonists for treatment of mental disorders |
| US20180049994A1 (en) | 2016-08-16 | 2018-02-22 | Afgin Pharma, Llc | Topical regional neuro-affective therapy with caryophyllene |
| US20190241962A1 (en) * | 2016-10-02 | 2019-08-08 | Sharon Anavi-Goffer | Genetic susceptibility diagnosis and treatment of mental disorders |
| CN115379832A (zh) * | 2020-03-10 | 2022-11-22 | 学校法人近畿大学 | 含有石竹烯的剂、组合物及各种用途 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040072824A1 (en) * | 2001-06-01 | 2004-04-15 | Adam Telerman | Methods and compositions for the treatment of cancer |
| US20070154534A1 (en) * | 2003-03-12 | 2007-07-05 | Sheitman Brian B | Use of secretin in the treatment of schizophrenia |
| DK1753764T3 (da) * | 2004-06-09 | 2009-02-16 | Glaxo Group Ltd | Pyrrolopyridin-derivater |
| WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
| BR122016029094B1 (pt) * | 2004-10-01 | 2021-10-13 | Aché Laboratórios Farmacêuticos S.A | Composição farmacêutica anti-inflamatória |
| US7923465B2 (en) * | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
| PT1903866E (pt) * | 2005-11-07 | 2016-06-09 | Murty Pharmaceuticals Inc | Distribuição melhorada de tetra-hidrocanabinol |
| CA2650566A1 (en) * | 2006-04-27 | 2007-11-08 | Solvay Pharmaceuticals Gmbh | Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators |
| CA2688570A1 (en) * | 2007-05-31 | 2008-12-04 | F.P.L. Pharma Inc. | Compositions for prevention or treatment of anorexia-cachexia syndrome and uses thereof |
| KR20110073653A (ko) | 2009-12-24 | 2011-06-30 | 충북대학교 산학협력단 | 4-ｏ-메틸호노키올을 유효 성분으로 함유하는 항-불안 예방 및 치료용 의약 조성물 |
| JP6326563B2 (ja) | 2012-03-19 | 2018-05-23 | アリエル−ユニバーシティー リサーチ アンド デベロップメント カンパニー リミテッド | β−カリオフィレンとＣＢ２受容体アゴニストを用いた精神病の治療 |
| US9486419B2 (en) | 2013-04-17 | 2016-11-08 | Ariel-University Research And Development Company | CB2 receptor ligands for the treatment of psychiatric disorders |
| US20190241962A1 (en) | 2016-10-02 | 2019-08-08 | Sharon Anavi-Goffer | Genetic susceptibility diagnosis and treatment of mental disorders |
| WO2018112138A1 (en) | 2016-12-15 | 2018-06-21 | Anavi Goffer Sharon | Treatment of mental, movement and behavioral disorders |
-
2013
- 2013-03-19 JP JP2015501032A patent/JP6326563B2/ja not_active Expired - Fee Related
- 2013-03-19 WO PCT/IB2013/052182 patent/WO2013140342A1/en not_active Ceased
- 2013-03-19 EP EP13763464.8A patent/EP2827846B1/en not_active Not-in-force
- 2013-03-19 US US14/385,739 patent/US20150051299A1/en not_active Abandoned
-
2017
- 2017-02-14 US US15/432,198 patent/US20170151182A1/en not_active Abandoned
-
2020
- 2020-05-08 US US16/869,672 patent/US11612572B2/en active Active
-
2023
- 2023-02-27 US US18/175,252 patent/US20230218540A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539144A5 (enExample) | ||
| JP2015537003A5 (enExample) | ||
| JP2011508765A5 (enExample) | ||
| JP2010535220A5 (enExample) | ||
| TW201306840A (zh) | 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌□反其鹽用於治療精神分裂症的方法 | |
| GEP20125379B (en) | 2 -pyridine carboxamide derivatives as sodium channel modulators | |
| JP2012524112A5 (enExample) | ||
| MX2009011619A (es) | Formulaciones que contienen clopidogrel y eter sulfoalquilico-ciclodextrina y metodos de uso. | |
| HRP20201916T1 (hr) | Trifluorometil supstituirani pirazoli kao inhibitori kalikreina u ljudskoj plazmi | |
| CA2932610A1 (en) | Heterocycle fused gamma-carboline compounds for use in treatment of schizophrenia | |
| EA201170527A1 (ru) | Фармацевтические композиции, включающие соединения бороновой кислоты | |
| CA2671954A1 (en) | Methods for treating or preventing symptoms of hormonal variations | |
| IL188643A (en) | Derivatives – n (troaryl) –1 – troarylalkyl – 1h – indole – 2– carboxamide, process for the production of derivatives, drug, pharmaceutical composition and use of derivatives for drug production. | |
| HRP20120918T1 (hr) | Aminopirazolski spoj | |
| UA107353C2 (en) | Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof | |
| NZ569331A (en) | COP 1 for treatment of inflammatory bowel diseases | |
| JP2010511596A5 (enExample) | ||
| RU2011137131A (ru) | Производные 1-аминоалкилциклогексана для лечения тиннитуса, связанного с потерей слуха или незначительной потерей слуха | |
| WO2008006795A3 (en) | Indole compounds | |
| JP2015510916A5 (enExample) | ||
| JP2015510928A5 (enExample) | ||
| PH12017501831A1 (en) | Pharmaceutical compositions for oral administration | |
| JP2017520588A5 (enExample) | ||
| JP2016514688A5 (enExample) | ||
| MD4538B1 (ro) | 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei |